Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service ERCP & endoscopic ultrasound cases in Nevada: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (240 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 754 | 42% |
| 2020 | 12 | 682 | 45% |
| 2021 | 9 | 625 | 48% |
Biliary stenting, stone extraction, EUS with FNA; the advanced-endoscopy call point. Professional codes (what the surgeon bills): CPT 43264, 43274, 43260, 43259, 43242, 43266.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Nevada; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 165 | 12,633+0.7%/yr | +0.7%/yr | 3.9 | 1% | 15,600 in 2030+3.6%/yr |
| Washington | 46 | 2,920 |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Colonoscopy & upper endoscopy | 98 | 24,594−2.4%/yr | −2.4%/yr | 89.00.8× | 70% | 25,500 in 2030+0.6%/yr |
| Bronchoscopy & lung nodule |
ERCP & endoscopic ultrasound in every state, and its device makers · Every procedure market in Nevada · Every state · Compare with California
| 2024 |
| 659 |
| 56% |
| 2025 est. | ≈ 570 | – |
| 2026 est. | ≈ 580 | – |
| 2022 | 13 | 703 | 51% |
| 2023 | 10 | 644 | 54% |
| 2024 | 10 | 659 | 56% |
| 2025 from claims | – | 571 462–671 | 57% |
| 2026 forecast | – | 580 455–729 | 57% |
| 2027 forecast | – | 587 435–776 | 58% |
| 2028 forecast | – | 593 420–819 | 58% |
| 2029 forecast | – | 600 407–860 | 59% |
| 2030 forecast | – | 606 397–899 | 60% |
In 2025, 62% inpatient hospital, 38% hospital outpatient.
| −2.5%/yr |
| 3.9 |
| 0% |
| 3,710 in 2030+4.1%/yr |
| Arizona | 36 | 2,770+2.8%/yr | +2.8%/yr | 3.8 | 2% | 3,300 in 2030+3%/yr |
| Colorado | 25 | 1,932+0.7%/yr | +0.7%/yr | 4.1 | 0% | 2,030 in 2030+0.9%/yr |
| Oregon | 26 | 1,050−5.1%/yr | −5.1%/yr | 2.6 | 0% | 1,370 in 2030+4.6%/yr |
| Idaho | 12 | 559+4.8%/yr | +4.8%/yr | 2.8 | 0% | 1,080 in 2030+12%/yr |
| Utah | 12 | 445−6.8%/yr | −6.8%/yr | 2.1 | 0% | 480 in 2030+1.3%/yr |
| Montana | 8 | 373−4.1%/yr | −4.1%/yr | 2.0 | 0% | 440 in 2030+2.8%/yr |
| New Mexico | 8 | 365−15%/yr | −15%/yr | 1.6 | 0% | 390 in 2030+1.1%/yr |
| Alaska | 4 | 213+6.2%/yr | +6.2%/yr | 1.8 | 0% | 220 in 2030+0.8%/yr |
| Hawaii | 5 | 193−5.6%/yr | −5.6%/yr | 1.5 | 1% | 340 in 2030+10%/yr |
| 11 |
| 545+13%/yr |
| +13%/yr |
| 1.90.8× |
| 0% |
| 870 in 2030+8.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Steris leads with 32% of company spending on these surgeons in 2025, +24 pts on 2024.
In 2025, 9 companies reported engagement with Nevada’s surgeons worth $2,996 in consulting, speaking, meals and travel tied to these products, about $300 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 7 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.